CN115433268B - 一种肿瘤抑制肽 - Google Patents

一种肿瘤抑制肽

Info

Publication number
CN115433268B
CN115433268B CN202111153273.6A CN202111153273A CN115433268B CN 115433268 B CN115433268 B CN 115433268B CN 202111153273 A CN202111153273 A CN 202111153273A CN 115433268 B CN115433268 B CN 115433268B
Authority
CN
China
Prior art keywords
amino acid
polypeptide
endostatin
leu
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111153273.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN115433268A (zh
Inventor
刘宏利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hep Pharmaceutical Co ltd
Original Assignee
Shanghai Hep Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hep Pharmaceutical Co ltd filed Critical Shanghai Hep Pharmaceutical Co ltd
Publication of CN115433268A publication Critical patent/CN115433268A/zh
Application granted granted Critical
Publication of CN115433268B publication Critical patent/CN115433268B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202111153273.6A 2015-07-27 2016-07-21 一种肿瘤抑制肽 Active CN115433268B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201510446747 2015-07-27
CN2015104467474 2015-07-27
CN201680044076.1A CN107922475B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
PCT/CN2016/090800 WO2017016430A1 (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680044076.1A Division CN107922475B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽

Publications (2)

Publication Number Publication Date
CN115433268A CN115433268A (zh) 2022-12-06
CN115433268B true CN115433268B (zh) 2025-10-03

Family

ID=57883958

Family Applications (17)

Application Number Title Priority Date Filing Date
CN202111153273.6A Active CN115433268B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN201680044076.1A Active CN107922475B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111153334.9A Active CN115433270B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111152259.4A Active CN113717276B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111155210.4A Active CN113943364B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111151032.8A Active CN113717274B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111155244.3A Active CN114031683B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111155546.0A Active CN113980120B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111152268.3A Active CN113717277B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111153255.8A Active CN115433267B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111155262.1A Active CN113943365B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111152378.XA Active CN113912705B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111155175.6A Active CN113943363B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111152258.XA Active CN113717275B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111153309.0A Active CN115433269B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111152272.XA Active CN113717278B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111155543.7A Active CN113980119B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽

Family Applications After (16)

Application Number Title Priority Date Filing Date
CN201680044076.1A Active CN107922475B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111153334.9A Active CN115433270B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111152259.4A Active CN113717276B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111155210.4A Active CN113943364B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111151032.8A Active CN113717274B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111155244.3A Active CN114031683B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111155546.0A Active CN113980120B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111152268.3A Active CN113717277B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111153255.8A Active CN115433267B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111155262.1A Active CN113943365B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111152378.XA Active CN113912705B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111155175.6A Active CN113943363B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111152258.XA Active CN113717275B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111153309.0A Active CN115433269B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111152272.XA Active CN113717278B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111155543.7A Active CN113980119B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽

Country Status (5)

Country Link
US (1) US10351613B2 (enExample)
EP (1) EP3330285B1 (enExample)
JP (1) JP6903633B2 (enExample)
CN (17) CN115433268B (enExample)
WO (1) WO2017016430A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115433268B (zh) * 2015-07-27 2025-10-03 上海贺普药业股份有限公司 一种肿瘤抑制肽
CN113244370A (zh) * 2020-02-13 2021-08-13 珠海市藤栢医药有限公司 一种预防和/或治疗神经母细胞瘤的多肽药物及其用途
CN115991739B (zh) * 2021-12-20 2023-10-20 珠海市藤栢医药有限公司 一种抗肿瘤的多肽及其制备方法和应用
CN117801060A (zh) * 2022-09-26 2024-04-02 深圳碳云智肽药物科技有限公司 一种抗肿瘤多肽及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102133407A (zh) * 2002-03-01 2011-07-27 图兰恩教育基金管理人 治疗剂或细胞毒性剂与生物活性肽的偶联物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0857210B1 (en) * 1995-10-23 2003-09-03 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US6174861B1 (en) * 1996-10-22 2001-01-16 The Children's Medical Center Corporation Methods of inhibiting angiogenesis via increasing in vivo concentrations of endostatin protein
US6825167B1 (en) * 2000-04-03 2004-11-30 Regents Of The University Of Minnesota Genetic modification of endostatin
CN1239516C (zh) * 2002-02-08 2006-02-01 中国医学科学院基础医学研究所 肿瘤坏死因子相关细胞凋亡诱导配体胞外区突变多肽及其制法与用途
US20040091465A1 (en) * 2002-06-26 2004-05-13 Zachary Yim Therapeutic antiangiogenic compositions and methods
US7078485B2 (en) * 2002-12-05 2006-07-18 Yantai Medgenn Ltd. N-terminal modified recombinant human endostatin and its production
US7524811B2 (en) * 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
CN1875104A (zh) * 2003-08-29 2006-12-06 儿童医学中心公司 来自内皮抑素n－末端的抗血管生成肽
JP2007525972A (ja) * 2003-08-29 2007-09-13 チルドレンズ メディカル センター コーポレーション エンドスタチンのｎ末端からの抗血管新生性ペプチド
ES2325344B1 (es) * 2004-11-02 2010-06-09 Univ Madrid Autonoma Inhibidores de angiogenesis multifuncionales y multivalentes.
CN101062954A (zh) * 2006-05-16 2007-10-31 中国人民解放军军事医学科学院野战输血研究所 具有抗血管生成作用的融合蛋白及其编码基因与应用
CN100586961C (zh) * 2006-05-16 2010-02-03 中国人民解放军军事医学科学院野战输血研究所 对肿瘤细胞具有抑制作用的融合蛋白及其编码基因与应用
ES2385115T3 (es) * 2007-04-11 2012-07-18 Gene Signal International Sa Fármaco, medicamento, composición antitumorales y su uso
CN101096671A (zh) * 2007-06-01 2008-01-02 徐寒梅 血管生成抑制剂hm-x及其制备方法和应用
WO2009003145A1 (en) * 2007-06-26 2008-12-31 University Of Miami Antibody-endostatin fusion protein and its variants
CN102924578A (zh) * 2011-08-09 2013-02-13 哈药集团技术中心 抗肿瘤多肽及其制备方法和抗肿瘤应用
EP2561888A1 (en) * 2011-08-23 2013-02-27 Deutsches Krebsforschungszentrum Protein comprising NC-1 for treating angiogenesis-related diseases
CN115433268B (zh) * 2015-07-27 2025-10-03 上海贺普药业股份有限公司 一种肿瘤抑制肽

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102133407A (zh) * 2002-03-01 2011-07-27 图兰恩教育基金管理人 治疗剂或细胞毒性剂与生物活性肽的偶联物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
type XVIII collagen long variant [Homo sapiens];GenBank: AAR83296.1;NCBI;20160610;1-4 *

Also Published As

Publication number Publication date
CN115433270A (zh) 2022-12-06
CN115433267B (zh) 2026-03-27
CN113943364A (zh) 2022-01-18
CN107922475B (zh) 2021-08-27
JP6903633B2 (ja) 2021-07-14
EP3330285A4 (en) 2019-01-09
CN113943363A (zh) 2022-01-18
CN113943364B (zh) 2024-02-02
CN113943365A (zh) 2022-01-18
CN113980119A (zh) 2022-01-28
CN113717276B (zh) 2024-02-02
US10351613B2 (en) 2019-07-16
CN113717274B (zh) 2023-11-28
CN113943365B (zh) 2023-12-08
CN113717274A (zh) 2021-11-30
CN113717278B (zh) 2024-02-02
CN113717275B (zh) 2024-02-02
CN115433267A (zh) 2022-12-06
CN114031683B (zh) 2023-12-26
CN113980120B (zh) 2024-06-04
CN113943363B (zh) 2023-11-28
CN113717278A (zh) 2021-11-30
CN113912705B (zh) 2023-12-22
CN113717277B (zh) 2024-02-02
WO2017016430A1 (zh) 2017-02-02
EP3330285B1 (en) 2022-08-31
CN107922475A (zh) 2018-04-17
CN115433268A (zh) 2022-12-06
CN113717275A (zh) 2021-11-30
CN113717276A (zh) 2021-11-30
JP2018526987A (ja) 2018-09-20
CN113980120A (zh) 2022-01-28
CN113717277A (zh) 2021-11-30
US20190010201A1 (en) 2019-01-10
CN113912705A (zh) 2022-01-11
CN115433269B (zh) 2025-10-17
CN114031683A (zh) 2022-02-11
CN113980119B (zh) 2024-05-28
EP3330285A1 (en) 2018-06-06
CN115433269A (zh) 2022-12-06
CN115433270B (zh) 2025-10-14

Similar Documents

Publication Publication Date Title
CN115433267B (zh) 一种肿瘤抑制肽
US20200062811A1 (en) Yap protein inhibiting polypeptide and application thereof
CN108295244B (zh) 用于治疗乳腺肿瘤的多肽
CN108299556B (zh) 一种治疗血液肿瘤的多肽
CN111094357B (zh) 一类新的Bcl10聚合抑制剂及其应用
CN119661656B (zh) 一种靶向拮抗pCAV1的多肽及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant